Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Laryngostenosis | 6 | 2023 | 37 | 0.860 |
Why?
|
| Papilloma | 8 | 2003 | 22 | 0.440 |
Why?
|
| Vocal Cord Paralysis | 3 | 2022 | 66 | 0.410 |
Why?
|
| Laryngeal Neoplasms | 4 | 2019 | 85 | 0.370 |
Why?
|
| Vocal Cords | 4 | 2022 | 61 | 0.360 |
Why?
|
| Voice Disorders | 3 | 2003 | 16 | 0.300 |
Why?
|
| Laryngoplasty | 2 | 2022 | 28 | 0.290 |
Why?
|
| Laryngoscopy | 4 | 2021 | 158 | 0.290 |
Why?
|
| Zenker Diverticulum | 1 | 2008 | 5 | 0.280 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2019 | 753 | 0.270 |
Why?
|
| Esophagoscopy | 1 | 2008 | 173 | 0.260 |
Why?
|
| Respiratory Tract Neoplasms | 5 | 1994 | 9 | 0.210 |
Why?
|
| Bronchial Neoplasms | 2 | 2003 | 15 | 0.210 |
Why?
|
| Tracheal Neoplasms | 2 | 2003 | 21 | 0.210 |
Why?
|
| Papillomaviridae | 2 | 2003 | 178 | 0.200 |
Why?
|
| Aorta, Thoracic | 2 | 2018 | 527 | 0.190 |
Why?
|
| Parkinsonian Disorders | 1 | 2003 | 79 | 0.190 |
Why?
|
| Collagen | 1 | 2003 | 277 | 0.180 |
Why?
|
| Botulinum Toxins | 2 | 1996 | 112 | 0.180 |
Why?
|
| Voice Quality | 2 | 2016 | 21 | 0.170 |
Why?
|
| Tracheotomy | 1 | 2001 | 33 | 0.170 |
Why?
|
| Cricoid Cartilage | 1 | 2020 | 14 | 0.160 |
Why?
|
| Recurrent Laryngeal Nerve Injuries | 2 | 2018 | 14 | 0.160 |
Why?
|
| Treatment Outcome | 13 | 2023 | 12853 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2003 | 604 | 0.150 |
Why?
|
| Radiodermatitis | 1 | 2019 | 9 | 0.150 |
Why?
|
| Administration, Topical | 1 | 2019 | 131 | 0.150 |
Why?
|
| Esomeprazole | 1 | 2019 | 33 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2003 | 727 | 0.150 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 157 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2003 | 1275 | 0.140 |
Why?
|
| Postoperative Complications | 3 | 2018 | 3105 | 0.140 |
Why?
|
| Larynx | 2 | 2018 | 72 | 0.140 |
Why?
|
| Fibrosis | 1 | 2019 | 419 | 0.130 |
Why?
|
| Ethmoid Sinus | 1 | 1997 | 9 | 0.130 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 1997 | 9 | 0.130 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 1997 | 18 | 0.130 |
Why?
|
| Neurilemmoma | 2 | 1997 | 41 | 0.130 |
Why?
|
| Verbal Behavior | 1 | 1996 | 44 | 0.120 |
Why?
|
| Tracheostomy | 2 | 2015 | 212 | 0.120 |
Why?
|
| Tracheal Diseases | 1 | 2015 | 13 | 0.120 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 1302 | 0.120 |
Why?
|
| Disease Management | 1 | 2019 | 559 | 0.110 |
Why?
|
| Middle Aged | 19 | 2022 | 28393 | 0.110 |
Why?
|
| Multiple Endocrine Neoplasia | 3 | 1992 | 24 | 0.110 |
Why?
|
| Osteochondrodysplasias | 1 | 2015 | 69 | 0.110 |
Why?
|
| Critical Care | 1 | 2001 | 684 | 0.110 |
Why?
|
| Isotretinoin | 2 | 1994 | 19 | 0.110 |
Why?
|
| Tourette Syndrome | 1 | 1996 | 155 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 4 | 2002 | 633 | 0.110 |
Why?
|
| Tracheal Stenosis | 1 | 2014 | 30 | 0.110 |
Why?
|
| Amyloidosis | 3 | 1992 | 69 | 0.110 |
Why?
|
| Recurrence | 3 | 2021 | 1475 | 0.110 |
Why?
|
| Adult | 21 | 2021 | 31122 | 0.100 |
Why?
|
| Skin Diseases | 3 | 1992 | 141 | 0.100 |
Why?
|
| Airway Obstruction | 1 | 2015 | 177 | 0.100 |
Why?
|
| Male | 25 | 2022 | 64506 | 0.100 |
Why?
|
| Radiotherapy, Conformal | 3 | 2002 | 50 | 0.100 |
Why?
|
| Humans | 37 | 2023 | 130444 | 0.100 |
Why?
|
| Retrospective Studies | 11 | 2023 | 17633 | 0.090 |
Why?
|
| Quality of Life | 3 | 2020 | 2070 | 0.090 |
Why?
|
| Prospective Studies | 7 | 2023 | 6445 | 0.090 |
Why?
|
| Female | 24 | 2022 | 70349 | 0.090 |
Why?
|
| Inflammation | 1 | 2019 | 1480 | 0.090 |
Why?
|
| Reoperation | 2 | 2020 | 830 | 0.090 |
Why?
|
| Spasm | 2 | 1990 | 46 | 0.090 |
Why?
|
| Facial Paralysis | 1 | 1990 | 36 | 0.080 |
Why?
|
| Cranial Nerve Diseases | 1 | 1990 | 28 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2019 | 3691 | 0.080 |
Why?
|
| Constriction, Pathologic | 2 | 2023 | 227 | 0.080 |
Why?
|
| Interferon Type I | 3 | 1991 | 116 | 0.080 |
Why?
|
| Aged, 80 and over | 6 | 2008 | 6771 | 0.070 |
Why?
|
| Esophageal Sphincter, Upper | 1 | 2008 | 5 | 0.070 |
Why?
|
| Dystonia | 1 | 1990 | 169 | 0.070 |
Why?
|
| Aged | 11 | 2019 | 20897 | 0.070 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 5204 | 0.070 |
Why?
|
| Veterans | 1 | 2019 | 1792 | 0.070 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 4013 | 0.060 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 1985 | 6 | 0.060 |
Why?
|
| Cranial Nerves | 1 | 1985 | 21 | 0.060 |
Why?
|
| Facial Neoplasms | 1 | 1985 | 23 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 2003 | 1608 | 0.060 |
Why?
|
| Adolescent | 11 | 2018 | 20734 | 0.060 |
Why?
|
| Radiation Injuries | 2 | 2002 | 147 | 0.050 |
Why?
|
| Time Factors | 3 | 2021 | 6188 | 0.050 |
Why?
|
| Injections, Intramuscular | 2 | 1996 | 183 | 0.050 |
Why?
|
| Xerostomia | 1 | 2002 | 13 | 0.050 |
Why?
|
| Vascular Surgical Procedures | 2 | 2018 | 536 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 729 | 0.040 |
Why?
|
| Skin | 2 | 2019 | 543 | 0.040 |
Why?
|
| Radiotherapy | 2 | 2019 | 120 | 0.040 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1233 | 0.040 |
Why?
|
| Angiofibroma | 1 | 2000 | 5 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 451 | 0.040 |
Why?
|
| Risk Factors | 2 | 2019 | 10983 | 0.040 |
Why?
|
| Heme Oxygenase-1 | 1 | 2019 | 33 | 0.040 |
Why?
|
| Glottis | 1 | 2019 | 29 | 0.040 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 1999 | 32 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2019 | 120 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 259 | 0.040 |
Why?
|
| Melanoma | 1 | 1985 | 917 | 0.040 |
Why?
|
| Models, Anatomic | 1 | 2019 | 107 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2019 | 130 | 0.030 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2018 | 36 | 0.030 |
Why?
|
| Prognosis | 2 | 2019 | 4904 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 2018 | 154 | 0.030 |
Why?
|
| Inpatients | 1 | 2022 | 549 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 900 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 298 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 299 | 0.030 |
Why?
|
| Voice | 1 | 2016 | 13 | 0.030 |
Why?
|
| Early Medical Intervention | 1 | 2016 | 29 | 0.030 |
Why?
|
| Child | 10 | 2003 | 26162 | 0.030 |
Why?
|
| Wound Healing | 1 | 2019 | 476 | 0.030 |
Why?
|
| Child, Preschool | 5 | 2003 | 14985 | 0.030 |
Why?
|
| Infant | 4 | 2003 | 13281 | 0.030 |
Why?
|
| Neuroendocrine Tumors | 1 | 1995 | 69 | 0.030 |
Why?
|
| United States | 2 | 2021 | 11828 | 0.030 |
Why?
|
| Nose Neoplasms | 2 | 2000 | 32 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 2134 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2016 | 442 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1994 | 60 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 716 | 0.030 |
Why?
|
| Carcinoma | 2 | 1993 | 285 | 0.020 |
Why?
|
| Thyroid Neoplasms | 2 | 1993 | 249 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1828 | 0.020 |
Why?
|
| Administration, Oral | 1 | 1994 | 695 | 0.020 |
Why?
|
| Radiography | 1 | 1994 | 750 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2019 | 1605 | 0.020 |
Why?
|
| Radiotherapy Dosage | 2 | 2002 | 221 | 0.020 |
Why?
|
| Young Adult | 2 | 2016 | 9975 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3344 | 0.020 |
Why?
|
| Facial Muscles | 1 | 1990 | 25 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 4700 | 0.020 |
Why?
|
| Electromyography | 1 | 1990 | 139 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 3030 | 0.020 |
Why?
|
| Pedigree | 2 | 1993 | 1683 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 1994 | 1323 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 5083 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1891 | 0.020 |
Why?
|
| Calcitonin | 1 | 1989 | 29 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4660 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1994 | 1311 | 0.020 |
Why?
|
| Pharyngeal Neoplasms | 1 | 1985 | 19 | 0.010 |
Why?
|
| Melanocytes | 1 | 1985 | 45 | 0.010 |
Why?
|
| Schwann Cells | 1 | 1985 | 62 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1985 | 310 | 0.010 |
Why?
|
| Biopsy | 1 | 1989 | 1237 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1985 | 427 | 0.010 |
Why?
|
| Parotid Gland | 1 | 2002 | 18 | 0.010 |
Why?
|
| Interferons | 1 | 1983 | 136 | 0.010 |
Why?
|
| Mice | 1 | 2019 | 18203 | 0.010 |
Why?
|
| Remission Induction | 1 | 1991 | 299 | 0.010 |
Why?
|
| Antibodies | 1 | 1991 | 320 | 0.010 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2000 | 59 | 0.010 |
Why?
|
| Immobilization | 1 | 1999 | 23 | 0.010 |
Why?
|
| Technology, Radiologic | 1 | 1999 | 11 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1999 | 61 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2000 | 630 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 33909 | 0.010 |
Why?
|
| Random Allocation | 2 | 1988 | 416 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1999 | 814 | 0.010 |
Why?
|
| Ploidies | 1 | 1995 | 35 | 0.010 |
Why?
|
| Carcinoid Tumor | 1 | 1995 | 24 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1995 | 286 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 1988 | 1125 | 0.010 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 1993 | 6 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1995 | 767 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 1994 | 240 | 0.010 |
Why?
|
| Genes | 1 | 1993 | 310 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1993 | 597 | 0.010 |
Why?
|
| Meige Syndrome | 1 | 1990 | 7 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1994 | 1451 | 0.000 |
Why?
|
| Pheochromocytoma | 1 | 1989 | 32 | 0.000 |
Why?
|
| Hypothyroidism | 1 | 1990 | 77 | 0.000 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1989 | 67 | 0.000 |
Why?
|
| Tremor | 1 | 1990 | 125 | 0.000 |
Why?
|
| DNA | 1 | 1993 | 1419 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1988 | 297 | 0.000 |
Why?
|
| Biomarkers, Tumor | 1 | 1995 | 1608 | 0.000 |
Why?
|
| DNA, Viral | 1 | 1988 | 452 | 0.000 |
Why?
|
| Adenoma, Pleomorphic | 1 | 1985 | 9 | 0.000 |
Why?
|
| Neurofibroma | 1 | 1985 | 7 | 0.000 |
Why?
|
| Paraganglioma | 1 | 1985 | 22 | 0.000 |
Why?
|
| Laser Therapy | 1 | 1988 | 241 | 0.000 |
Why?
|
| Angiography | 1 | 1985 | 184 | 0.000 |
Why?
|
| Drug Compounding | 1 | 1983 | 40 | 0.000 |
Why?
|
| Lymphoma | 1 | 1985 | 328 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1985 | 2109 | 0.000 |
Why?
|